TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6583715

Group type: EXPERIMENTAL
Intervention: Des-Tyr-gamma-endorphin (DT gamma E) 1 mg, i.m., for 8 consecutive days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30584682

Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with a non-occluding temporary crown (test group, n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (left without a crown, n = 9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 29801519

Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 27703328

Group type: EXPERIMENTAL
Intervention: 5 mg intrathecal pethidine (P5 group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10 mg intrathecal pethidine (P10 group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard group (S group) with 0.5 mL of 0.9% saline
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard group (S group)
Number of subjects: 150
Study: 25374024

Group type: EXPERIMENTAL
Intervention: Curcuminoids supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21814149

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (SUP)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 122
Study: 20412091

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immediate restoration group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 18632147

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg intravenously at 28-day intervals for 6 months)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (10 mg/kg at 28-day intervals for 6 months)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 15924546

Group type: EXPERIMENTAL
Intervention: Oral antibiotics given prior to delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 11527656

Group type: EXPERIMENTAL
Intervention: Vitamin and trace-element supplementation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9722224

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and heat-exchange (MVHE) units
Number of subjects: 10
Study: 8035577

Group type: EXPERIMENTAL
Intervention: Enhanced Alcohol Misuse Prevention Study (AMPS) curriculum emphasizing social pressure resistance training, peer support, and norm-setting.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (curriculum not specified).
Number of subjects: 0
Study: 2499342

Group type: EXPERIMENTAL
Intervention: GTN spray (Nitro‐Corangin Spray)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Another GTN Spray
Number of subjects: 12
Study: 977927

Group type: EXPERIMENTAL
Intervention: 3-hour training program
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (received training after research program)
Number of subjects: 322
Study: 30817019

Group type: EXPERIMENTAL
Intervention: Greater AUD severity
Number of subjects: 100

Group type: COMPARATOR
Intervention: All participants
Number of subjects: 100
Study: 28007678

Group type: EXPERIMENTAL
Intervention: ERA+probiotic (Bifidobacterium animalis subsp. lactis B94, 1 capsule/day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: ERA+placebo (1 capsule/day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: ERA-only (no additional treatments)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Combined ERA (ERA+placebo and ERA-only)
Number of subjects: 159
Study: 26844861

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24222009

Group type: EXPERIMENTAL
Intervention: Verbal discussion with handout
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal discussion alone
Number of subjects: 50
Study: 23121787

Group type: EXPERIMENTAL
Intervention: 12-week commercial weight loss program
Number of subjects: 111
Study: 19474651

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) 300 mg and ritonavir 100 mg daily for 6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 15
Study: 17507543

Group type: EXPERIMENTAL
Intervention: 6-day lymphocyte stimulation test (LST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: QuantiFERON‐TB Gold in‐tube (QFT‐GIT) test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: overnight enzyme‐linked immunospot assay (ELISPOT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: tuberculin skin test (TST)
Number of subjects: 40
Study: 15470330

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluconazole plus Rifabutin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 21
Study: 11355317

Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group I (30 patients with normal colonic transit time)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group II (30 patients with prolonged colonic transit time)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (normal and prolonged transit time)
Number of subjects: 75
Study: 9269803

Group type: EXPERIMENTAL
Intervention: Anal manometry feedback
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sphincter electromyography (EMG) feedback
Number of subjects: 26
Study: 8489563

Group type: EXPERIMENTAL
Intervention: 1000 mg/day HR
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 mg/day HR
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2881132

Group type: EXPERIMENTAL
Intervention: Penicillin (10(6) IU three times daily for 6 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 29613942

Group type: EXPERIMENTAL
Intervention: Atropine premedication during ECT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ROPL (Return of Pupillary Response to Light)
Number of subjects: 41
Study: 25775494

Group type: EXPERIMENTAL
Intervention: Tele-supervised functional electrical stimulation-assisted exercise (FES-ET) for 1 hour/day, 5 days/week for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tele-supervised functional electrical stimulation-assisted exercise (FES-ET)
Number of subjects: 0
Study: 24096180

Group type: EXPERIMENTAL
Intervention: Tdap vaccination with opt-in orders
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Tdap vaccination with standing orders
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Standard practice in comparison hospital
Number of subjects: 1264
Study: 24624877

Group type: EXPERIMENTAL
Intervention: ILK siRNA group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LY294002 group
Number of subjects: 6

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 6
Study: 20204951

Group type: EXPERIMENTAL
Intervention: Self-regulatory depletion manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 19463347

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention plus medical therapy (PCI+MT)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Initial medical therapy only (MT)
Number of subjects: 384
Study: 16627442

Group type: EXPERIMENTAL
Intervention: Single oral bolus propafenone (600 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: No oral bolus therapy (no bolus)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single oral bolus placebo
Number of subjects: 35
Study: 14674506

Group type: EXPERIMENTAL
Intervention: Dyract AP stored in de‐ionized water (D-W)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Spectrum TPH stored in silicone fluid (S-O)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Spectrum TPH stored in de‐ionized water (S-W)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Dyract AP stored in silicone fluid (D-O)
Number of subjects: 156
Study: 11184222

Group type: EXPERIMENTAL
Intervention: Group nutrition education (three meetings discussing positive health effects of a Mediterranean diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage-matched information based on the Transtheoretical Model of behavior change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group nutrition education and stage-matched information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individually stage-matched tailored letters
Number of subjects: 0
Study: 8790131

Group type: EXPERIMENTAL
Intervention: Structured encounter forms focused on developmental milestones (group 1)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Structured encounter forms focused on anticipatory guidance/preventive care (group 2)
Number of subjects: 206
Study: 8434380

Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard therapy without diltiazem (ND)
Number of subjects: 113
Study: 3319120

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel)
Number of subjects: 51

Group type: COMPARATOR
Intervention: L‐DOPA/carbidopa (Sinemet)
Number of subjects: 51
Study: 30017536

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 96
Study: 27373874

Group type: EXPERIMENTAL
Intervention: 163 kcal (very low energy meal, VLEM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 302 kcal (low energy meal, LEM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 605 kcal (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 889 kcal (high energy meal, HEM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1176 kcal (very high energy meal, VHEM)
Number of subjects: 27
Study: 25117895

Group type: EXPERIMENTAL
Intervention: Project Mothers and Schools (PMAS) initiative - group parenting time, life skills, and leadership training
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group - homebound education and family case management
Number of subjects: 115
Study: 23153177

Group type: EXPERIMENTAL
Intervention: Liraglutide added to insulin therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Insulin dose-increase
Number of subjects: 84
Study: 18729731

Group type: EXPERIMENTAL
Intervention: Combined folic acid and B-vitamin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin therapy
Number of subjects: 0
Study: 17724646

Group type: EXPERIMENTAL
Intervention: DIGITOS-prosthesis
Number of subjects: 16
Study: 15842827

Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sodium dimercaptopropane sulfonate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 12518724

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with antioxidants (vitamin E 200 mg/d and polyunsaturated fatty acids 1,000 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Photodynamic therapy only (no antioxidants)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with antioxidants
Number of subjects: 35

Group type: COMPARATOR
Intervention: Photodynamic therapy only
Number of subjects: 35
Study: 10097446

Group type: EXPERIMENTAL
Intervention: Osteometric dimensions of metacarpal bones (length, total diaphysis width, medullary canal width)
Number of subjects: 173
Study: 8172090

Group type: EXPERIMENTAL
Intervention: 10 g/d fiber supplement
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 20 g/d fiber supplement
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 29243270

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (mean BAC = 0.07%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Tonic water (control group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Belief of having consumed alcohol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Self-blame levels
Number of subjects: 79
Study: 27344348

Group type: EXPERIMENTAL
Intervention: 12-week table tennis exercise (group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 12-week table tennis exercise (group II)
Number of subjects: 32
Study: 25790451

Group type: EXPERIMENTAL
Intervention: H3-L6 intervention (increasing omega-3 fatty acids and reducing omega-6 linoleic acid)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: H3-L6 intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: L6 intervention (omega-6 lowering)
Number of subjects: 67
Study: 23924679

Group type: COMPARATOR
Intervention: 4 × 25-mg non-coated tablets
Number of subjects: 110

Group type: COMPARATOR
Intervention: 100-mg tablet dispersed in 100 ml water
Number of subjects: 110

Group type: COMPARATOR
Intervention: 200-mg non-coated and coated tablets
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 200-mg tablets
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 100-mg tablets
Number of subjects: 110
Study: 20334748

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Specialist outpatient treatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: General CAMHS treatment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Satisfaction measures
Number of subjects: 167
Study: 18990973

Group type: EXPERIMENTAL
Intervention: Lifestyle program (INTERCOM trial)
Number of subjects: 127
Study: 16487836

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Combination of captopril and valsartan
Number of subjects: 14703
Study: 14607306

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10767065

Group type: EXPERIMENTAL
Intervention: Three-dimensional contrast-enhanced moving-bed infusion-tracking (MoBI-track) peripheral MR angiography
Number of subjects: 7
Study: 8963977

Group type: EXPERIMENTAL
Intervention: Incremental field test (FT) using adapted Léger and Boucher test (ALBT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Laboratory test (LT) on adapted treadmill
Number of subjects: 9
Study: 1737593

Group type: EXPERIMENTAL
Intervention: Clinical measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mammographic measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination of clinical and mammographic measurements
Number of subjects: 200
Study: 6378516

Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment at home (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment in hospital (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 53
Study: 31322344

Group type: EXPERIMENTAL
Intervention: High-boiling but less-coordinating solvents (DMF) during coordination of dqp by [Ru(dqp)(MeCN)3]2+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-boiling but less-coordinating solvents (DMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [Ru(dqp)(MeCN)3]2+
Number of subjects: 0

Group type: COMPARATOR
Intervention: tpy
Number of subjects: 0
Study: 29073780

Group type: EXPERIMENTAL
Intervention: CWI with ropivacaine 2 mg/mL at a rate of 2 mL/h for 24 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CWI with ropivacaine
Number of subjects: 50
Study: 26111491

Group type: EXPERIMENTAL
Intervention: Advancing wheal technique
Number of subjects: 29

Group type: COMPARATOR
Intervention: Gale technique
Number of subjects: 29
Study: 24566756

Group type: EXPERIMENTAL
Intervention: beractant
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: poractant alfa
Number of subjects: 92
Study: 23012417

Group type: EXPERIMENTAL
Intervention: Dynamic reconfiguration of brain network during task preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-relevant visual areas
Number of subjects: 0
Study: 20974610

Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17949466

Group type: EXPERIMENTAL
Intervention: Nicotine (low dose 7 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nicotine (high dose 14 or 21 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (community controls)
Number of subjects: 55
Study: 16236688

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12487895

Group type: EXPERIMENTAL
Intervention: ILM peeling group (22 patients)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-ILM peeling group (19 patients)
Number of subjects: 41
Study: 10425951

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10 mg p.o.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acetaminophen codeine (325 mg/15 mg p.o.)
Number of subjects: 66
Study: 7498204

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg.day‐1 in twice divided doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2405720

Group type: EXPERIMENTAL
Intervention: Oral tetrahydroaminoacridine (THA) and lecithin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long-term treatment with THA and lecithin
Number of subjects: 10
Study: 7026336

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31821591

Group type: EXPERIMENTAL
Intervention: Efgartigimod 5 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Efgartigimod 10 mg/kg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30782756

Group type: EXPERIMENTAL
Intervention: Significant depressive symptoms (score of ≥6 on the Geriatric Depression Scale-15)
Number of subjects: 990
Study: 28002363

Group type: EXPERIMENTAL
Intervention: Single-level cervical total disc replacement (CTDR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single-level anterior cervical discectomy and fusion (ACDF)
Number of subjects: 34
Study: 25849523

Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention (14-week program with ten 90-minute group sessions and four individual telephone sessions)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 86
Study: 24008684

Group type: EXPERIMENTAL
Intervention: Internet-based preparation for inpatient psychosomatic psychotherapeutic treatment (VORSTAT)
Number of subjects: 176
Study: 21458107

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) 3 mg/kg
Number of subjects: 55
Study: 19381612

Group type: EXPERIMENTAL
Intervention: Subvastus approach (SV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional parapatellar approach
Number of subjects: 104
Study: 16719647

Group type: EXPERIMENTAL
Intervention: Familiar-appearing features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel-appearing features
Number of subjects: 0
Study: 14732872

Group type: EXPERIMENTAL
Intervention: CETP gene mutation (L296Q) carriers
Number of subjects: 203

Group type: COMPARATOR
Intervention: Healthy volunteers (controls)
Number of subjects: 203
Study: 11054648

Group type: EXPERIMENTAL
Intervention: IGF-I (80 microg/kg body weight, daily two s.c. injections for five days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (injections)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 15
Study: 9113634

Group type: EXPERIMENTAL
Intervention: HI20:4 diet (1.7 g/d arachidonic acid)
Number of subjects: 4

Group type: COMPARATOR
Intervention: LO20:4 diet (0.21 g/d arachidonic acid)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: HI20:4 diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: LO20:4 diet
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 4
Study: 8453254

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iodine-free formula-fed infants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iodine-supplemented formula-fed infants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Partially breast-fed infants
Number of subjects: 21
Study: 3532439

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride 10 mg intravenously every 12 hours for seven days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride
Number of subjects: 49
Study: 30500094

Group type: EXPERIMENTAL
Intervention: Two-implant overdenture (IOD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional reline of mandibular complete removable dental prostheses (CRDPs)
Number of subjects: 32
Study: 28426476

Group type: EXPERIMENTAL
Intervention: Intrasphincteric injections of autologous myoblasts (AM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delayed frozen AM injection in placebo group
Number of subjects: 24
Study: 26968807

Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 120
Study: 24701571

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isobaric levobupivacaine
Number of subjects: 60
Study: 22012130

Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rHuEPO) 40,000 units
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88